Genmab’s AI Revolution: Boosting Antibody Research with ChatGPT Enterprise Integration
Description
Genmab, a leading biotechnology company, is harnessing AI through ChatGPT Enterprise by OpenAI to bolster research and innovation in developing antibody therapies. Integrating AI into its operations, Genmab has expanded its "AI Everywhere" initiative to over 2,000 users, fostering a culture of continuous learning. Utilizing custom GPTs enhances tasks like document drafting, data analysis, and translating scientific texts. The rollout has improved efficiency, saving an average of 3.5 hours weekly per user. Genmab’s collaboration with OpenAI represents a strategic push toward advancing scientific discovery while ensuring robust data security and compliance.
Original article: https://innovationera.tech/2024/09/20/genmabs-ai-revolution-boosting-antibody-research-with-chatgpt-enterprise-integration/
United States
